CD96 and neoplasm: In addition to HLA-specific inhibitory and activating NK receptors—Killer-cell immunoglobulin-like receptors (KIRs), NK cells express inhibitory receptors including PD-1, TIGIT, CD96, TIM-3 and CD161 for anti-tumor activity [11].